Dr. Lal Path Labs to acquire subsidiary in Bangladesh
DSIJ Intelligence / 08 Aug 2017
Dr. Lal Path Labs has decided to acquire 70% stake in Dr. Lal Path Labs Bangladesh (DLPLB) from its existing shareholders with the objective of strengthening company’s presence in Bangladesh.
Dr. Lal Path Labs has decided to acquire 70% stake in Dr. Lal Path Labs Bangladesh (DLPLB) from its existing shareholders with the objective of strengthening company’s presence in Bangladesh.
Prior to the company’s acquisition, DLPLB shall be acquiring the diagnostics business of the sole proprietorship firm in Dhaka, Bangladesh.
Dr. Lal Path Labs will acquire the firm in an all-cash deal. The company’s acquisition will not exceed BDT 181.49 per share. There will be no government approval needed for the acquisition. The time for the proposed acquisition will be six months after the board’s approval.
DLPLB was incorporated on September 6, 2011, in Bangladesh. On the financial front, DLPLB’s turnover stood at BDT 3.1 crore in 2017 and BDT 3.3 crore in 2016.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.